Latest findings are from one of the largest experiences of neoadjuvant chemotherapy in upper tract urothelial carcinoma to date.
Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer.
Investigators report a 46% lower risk for death compared with chemotherapy alone.
Partial and radical nephrectomy for T3a RCC have similar 5-year rates of overall and cancer-specific survival, according to a propensity score-matched analysis.
Patients who experienced NMIBC recurrence were not at higher risk to recur with muscle-invasive or metastatic disease.
Real-world data demonstrate that multiparametric MRI has a lower negative predictive value than previously reported.
A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators report.
Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.
Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
